If you have been reading about CJC-1295 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
== History == The National Games were held every 5 years from 1985 to 1995, with the first National Games occurred in Hanoi, the games were held every five years (for three times), then it paused for almost a decade. It wasn't until 2002 that the next National Games, the 4th National Games, was held and since then the National Games has been held regularly every four years until the present.
=== Neurology === It is generally accepted that happiness is at least in part mediated through dopaminergic, adrenergic and serotonergic metabolism. A correlation has been found between hormone levels and happiness. SSRIs, such as Prozac, are used to adjust the levels of serotonin in the clinically unhappy. Researchers, such as Alexander, have indicated that many peoples usage of narcotics may be the unwitting result of attempts to readjust hormone levels to cope with situations that make them unhappy. A positive relationship has been found between the volume of gray matter in the right precuneus area of the brain and the subject's subjective happiness score. Meditation based interventions, including mindfulness, have been found to correlate with a significant gray matter increase within the precuneus.
=== Remediation of DNAPLs === Mitigation of LNAPLs tends to be less complex and require simpler engineering strategies. Conversely, DNAPLs can seep into cracks in the parent material of the subsurface, complicating both their movement and the technology required for their mitigation. In a best-case scenario, the DNAPL is continuous and has collected as a reservoir above the impermeable layer. In this scenario, a recovery well can be drilled and installed. When it comes to DNAPL remediation, the earlier it is removed, the better.
=== Medicine === Medical technicians may sequence genes (or, theoretically, full genomes) from patients to determine if there is risk of genetic diseases. This is a form of genetic testing, though not all genetic tests involve complete genome DNA sequencing. As of 2013 DNA sequencing was increasingly used to diagnose and treat rare diseases. As more and more genes are identified that cause rare genetic diseases, molecular diagnoses for patients become more mainstream. DNA sequencing allows clinicians to identify genetic diseases, improve disease management, provide reproductive counseling, and more effective therapies. Gene sequencing panels are used to identify multiple potential genetic causes of a suspected disorder. Also, DNA sequencing may be useful for determining a specific bacteria, to allow for more precise antibiotics treatments, hereby reducing the risk of creating antimicrobial resistance in bacteria populations.
60 years after the events of The Matrix Revolutions, Neo is now a video game designer and the creator of a video game series simply known as The Matrix, which uses Neo's previous memories in the plot. Neo is 57 years old in the Matrix program, but 60 years have passed in the real world, making Neo 97 years old. Neo once again lives under the alias Thomas Anderson and although he does not look old, others see him as an aging man with long gray hair. His love, Trinity, who lives under the name "Tiffany", is married to a man named Chad and has three children. Neo has a existential crisis, so his therapist has prescribed him the blue pills. Neo's boss approaches him with an idea to make a fourth Matrix game. However, the more Neo and his crew make the game, the less blue pills he takes and he eventually stops taking them. One day, a man known as "Morpheus" approaches Neo with the red pill, but agents and a police force storm the building where Neo works in order to kill Morpheus, who is revealed as a rogue agent who opened his mind and decided to help Neo destroy the Matrix (and has taken on the identity of the original Morpheus, who has since died). Morpheus kills several police officers while Neo's boss picks up an officer's gun and once again becomes Agent Smith. The attack was revealed to be a dream, and Neo was still in his therapist's room. A drunk Neo later goes on a rooftop and questions his existence. However, a woman with blue hair and a trench coat appears besides him. The woman introduces herself as Bugs, who tries to reopen his mind through a White Rabbit tattoo.
Sources: en.wikipedia.org
UPMC Bedford, located in Everett, Pennsylvania. UPMC Chautauqua, located in Jamestown, New York, is a 317-bed hospital that was originally charted in 1885. It is the only domestic hospital located outside of Pennsylvania to become part of the UPMC system. UPMC East, a $250 million full-service, 155-bed hospital that opened in Monroeville, Pennsylvania, in July 2012. UPMC Horizon, which consists of the Greenville and Shenango Valley campuses. UPMC Jameson, located in New Castle, Pennsylvania. UPMC McKeesport, located in McKeesport, Pennsylvania. UPMC Northwest, located in Seneca, Pennsylvania. UPMC St. Margaret, a 248-bed acute care and teaching hospital in the northeast corner of Pittsburgh, near Aspinwall, PA, serving the residents of northeastern Allegheny County and the Alle-Kiski Valley. UPMC Central Pa which comprises seven hospitals, including its tertiary flagship UPMC Harrisburg, serves South Central Pennsylvania, operates the following seven community hospitals: UPMC Carlisle located in Carlisle, Pennsylvania UPMC Hanover located in Hanover, Pennsylvania UPMC Lititz located in Lititz, Pennsylvania UPMC Memorial located in York, Pennsylvania has 104 beds, five stories, and opened in 2019.
=== Functional selectivity === A new strategy of drug development takes receptor signal transduction into consideration. This strategy strives to increase the activation of desirable signalling pathways while reducing the impact on undesirable pathways. This differential strategy has been given several names, including functional selectivity and biased agonism. The first opioid that was intentionally designed as a biased agonist and placed into clinical evaluation is the drug oliceridine. It displays analgesic activity and reduced adverse effects.
=== Litigation === This drug has been the subject of litigation; more than 13,000 people have sued Wyeth between 2002 and 2009. Wyeth and Pharmacia & Upjohn prevailed in the vast majority of hormone therapy cases previously set for trial through a combination of rulings by judges, verdicts by juries, and dismissals by plaintiffs themselves. Of the company's losses, two of the jury verdicts were reversed post-trial and others are being challenged on appeal. Wyeth also won five summary judgments on Prempro cases and had 15 cases voluntarily dismissed by plaintiffs. The company won dismissals in another 3,000 cases. In 2006, Mary Daniel, in a trial in Philadelphia, was awarded $1.5 million in compensatory damages as well as undisclosed punitive damages. As of 2010, Wyeth had won the last four of five cases, most recently in Virginia, finding that they were not responsible for the breast cancer of plaintiff Georgia Torkie-Tork. Wyeth has been quoted as saying "many risk factors associated with breast cancer have been identified, but science cannot establish what role any particular risk factor or combination play in any individual woman's breast cancer." Wyeth's counsel in the case also noted that in the WHI trial, 99.62% of women took the drug and "did not get breast cancer".
== Bibliography == Romualdo Verzosa Jr., ed. (1993). Encyclopedia of Chemical Technology, volume 6 (4th ed.). John Wiley & Sons. ISBN 978-0-471-52674-2. Masters, K (1991). Spray Drying Handbook (5th ed.). Longman Scientific & Technical. ISBN 978-0-582-06266-5. John J. McKetta, ed. (1995). Encyclopedia of Chemical Processing and Design. Marcel Dekker Inc. ISBN 978-0-8247-2604-1.
Sources: en.wikipedia.org
Vaccines typically contain attenuated, inactivated or dead organisms or purified products derived from them. There are several types of vaccines in use. These represent different strategies used to try to reduce the risk of illness while retaining the ability to induce a beneficial immune response.
==== Arrests ==== Sanlu general manager Tian Wenhua was charged under Articles 144 and 150 of the criminal code. A spokesman for the Hebei Provincial Public Security Department said police had arrested 12 milk dealers and suppliers who allegedly sold contaminated milk to Sanlu, and six people were charged with selling melamine. Three hundred kg (700 lb) of suspicious chemicals, including 223 kg (492 lb) of melamine, were confiscated. Among those arrested were two brothers who ran a milk collection centre in Hebei for allegedly supplying three tonnes of adulterated milk daily to the dairy; the owner of another collection centre which resold seven tons of milk a day to Sanlu, was arrested, and his operation was shut down. Zhang Yujun (alias Zhang Haitao), a former dairy farmer from Hebei, produced more than 600 tons of a "protein powder" mixture of melamine and maltodextrin from September 2007 to August 2008. He and eight other traders, dairy farm owners and milk purchasers who bought the powder from him were arrested in early October, bringing the total to 36. During the week of 22 December 2008, 17 people involved in producing, selling, buying and adding melamine in raw milk went on trial. Tian Wenhua, former Sanlu general manager, and three other company executives appeared in court in Shijiazhuang, charged with producing and selling milk contaminated with melamine. According to Xinhua, Tian pleaded guilty, and told the court she learned about the tainted milk complaints from consumers in mid-May.
===== Direct oral anticoagulants (DOACs) ===== DOACs are agents that inhibit the formation of thrombin which is the central effector of coagulation derived from factor Xa. They are categorised into direct thrombin inhibitors and direct factor Xa inhibitors. Direct thrombin inhibitors bind to the active sites of free or clot-bound thrombin to inhibit its effects. Dabigatran etexilate is a common example which has a rapid onset of action. Whereas direct factor Xa inhibitors including apixaban and rivaroxaban directly bind to clotting factor Xa to block its activity, thus inhibiting thrombin formation. DOACs are advantageous over warfarin because of a wider therapeutic window, which indicates safer and more effective use with minimal adverse effects. DOACs also have more stable and predictable anticoagulation effects. Therefore, routine coagulation monitoring is not required.
The party was named the Centre Party due to the fact that in Parliament the Catholics sat between the Liberals on the left and the Conservatives on the right as opposed to the party adhering to centrism in the modern context. Also in other German states Catholic parties were formed, cooperating with the Prussian Centre Party in the Reichstag:
=== Heart failure === DCA has been investigated as a treatment for post-ischemic recovery. There is also evidence that DCA improves metabolism by NADH production stimulation, but may lead to a depletion of NADH in normoxia.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.